Results 41 to 50 of about 957 (170)
New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam. [PDF]
Antimicrob Agents ChemotherABSTRACT Infections due to Carbapenem-resistant Acinetobacter baumannii (CRAB) are a significant burden and are associated with devastating outcomes.
Pogue JM +3 more
europepmc +3 more sources
Superbugs or multidrug resistant microbes: A new threat to the society
, 2023 Health Science Reports, Volume 6, Issue 8, August 2023.
Sakshi Painuli +3 more
wiley +1 more source
Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against Acinetobacter baumannii-calcoaceticus complex strains isolated from respiratory and bloodstream sources: results from ACNBio study [PDF]
Infections caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (ABC) are associated with high mortality rates and limited treatment options.
Hamilton-Seth, Robert +33 more
core +4 more sources
Clinical Infectious Diseases, 2023 Abstract Antimicrobial resistance in gram-negative pathogens, such as Acinetobacter baumannii, is a serious threat to human health. Sulbactam-durlobactam, a unique β-lactam and a β-lactamase inhibitor combination, is a novel agent targeted against carbapenem-resistant A. baumannii. This supplement provides a summary of the development of
Watkins, Richard R, Bonomo, Robert A
openaire +2 more sources
International Journal of Infectious DiseasesObjectives: This study aimed to evaluate the in vitro activity of cefiderocol and sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates from China and elucidate potential resistance mechanisms.
Yixin Zhang +5 more
doaj +1 more source
Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory
Antibiotics, 2023 The rapid emergence of multi-drug resistant Gram-negative pathogens has driven the introduction of novel β-lactam combination agents (BLCs) to the antibiotic market: ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem ...
Carmella Russo, Romney Humphries
doaj +1 more source
Boronic Acid Inhibitors of β‐Lactamases: A Promising Strategy Against Antimicrobial Resistance
Medicinal Research Reviews, EarlyView.ABSTRACT The rise of antimicrobial resistance (AMR) poses a critical threat to global health, mostly due to the proliferation of β‐lactamases, a class of enzymes responsible for the inactivation of β‐lactam antibiotics. Among the most promising strategies to restore β‐lactam efficacy is the use of β‐lactamase inhibitors (BLIs), with boronic acid ...
Nicolò Santi +4 more
wiley +1 more source
Journal of Antimicrobial Chemotherapy, 2020 AbstractObjectivesTo evaluate the activity of the novel broad-spectrum serine β-lactamase inhibitor durlobactam (ETX2514) combined with sulbactam against global isolates of carbapenem-resistant Acinetobacter baumannii with defined carbapenem resistance mechanisms compared with reference antimicrobials with known activity against Acinetobacter spp ...
Harald Seifert +5 more
openaire +2 more sources
Comparative Neurotoxicity of Polymyxin B and Colistin in Patients With Cancer
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 10, October 2026.ABSTRACT Background The polymyxins, polymyxin B and colistin, are last‐line options for the treatment of infections caused by drug‐resistant gram‐negative organisms. The comparative neurotoxicity of these agents using contemporary dosing is poorly understood.
Samuel L. Aitken +3 more
wiley +1 more source
Journal of Antimicrobial Chemotherapy, 2020 AbstractBackgroundDurlobactam is a broad-spectrum inhibitor of class A, C and D β-lactamases. Sulbactam is a generic β-lactam most commonly used as a β-lactamase inhibitor in combination with ampicillin; however, it has a unique property in that it has selective intrinsic activity against Acinetobacter baumannii.
Harald Reinhart +9 more
openaire +2 more sources